All posts by: Michael Zand

About Michael Zand

Antibiotic discovery in the abyss – Phys.Org

Continue reading

2017-11-15 NEWS

Phys.Org

Antibiotic discovery in the abyss
Phys.Org
Combining the innovations of synthetic biology with robotic environmental sampling, a team of University of Bristol researchers are travelling to some of the most ‘extreme’ environments on Earth, including Atlantic depths of 4.5km, to find new leads

Continue reading

2017-11-15 NEWS

Phase 1/2 study underway assessing Sangamo’s gene therapy for MPS II; shares ahead 6% premarket
Seeking Alpha
The first patient has been dosed in a Phase 1/2 clinical trial, CHAMPIONS, evaluating Sangamo Therapeutics’ (NASDAQ:SGMO) gene therapy SB-913 for the treatment of mucopolysaccharidosis type II (MPS II), an inherited lysosomal storage disorder in …

and more »